43 related articles for article (PubMed ID: 38743735)
1. Combination of Ethacrynic Acid and ATRA Triggers Differentiation and/or Apoptosis of Acute Myeloid Leukemia Cells through ROS.
Li L; Xi HM; Lu H; Cai X
Anticancer Agents Med Chem; 2024; 24(6):412-422. PubMed ID: 38204257
[TBL] [Abstract][Full Text] [Related]
2. Identification of triciribine as a novel myeloid cell differentiation inducer.
Suzuki S; Suzuki S; Sato-Nagaoka Y; Ito C; Takahashi S
PLoS One; 2024; 19(5):e0303428. PubMed ID: 38743735
[TBL] [Abstract][Full Text] [Related]
3. Fucosylation inhibitor 6-alkynylfucose enhances the ATRA-induced differentiation effect on acute promyelocytic leukemia cells.
Suzuki S; Liu J; Sato Y; Miyake R; Suzuki S; Okitsu Y; Fukuda T; Isaji T; Gu J; Takahashi S
Biochem Biophys Res Commun; 2024 May; 710():149541. PubMed ID: 38608490
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment.
Takahashi S
Hematol Rep; 2023 May; 15(2):331-346. PubMed ID: 37367084
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic principle(s) from
Sharma J; Prabha P; Sharma R; Gupta S; Dixit A
Cytotechnology; 2022 Oct; 74(5):591-611. PubMed ID: 36238266
[TBL] [Abstract][Full Text] [Related]
6. Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials.
Toson B; Fortes IS; Roesler R; Andrade SF
Pharmacol Res; 2022 Sep; 183():106403. PubMed ID: 35987481
[TBL] [Abstract][Full Text] [Related]
7. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy.
Takahashi S
Acta Haematol; 2022; 145(2):113-121. PubMed ID: 34673646
[TBL] [Abstract][Full Text] [Related]
8. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
[TBL] [Abstract][Full Text] [Related]
9. Vibsanin A sensitizes human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn.
Shen X; Xing S; Zhang L; Wang F; Ou H; Shan Y; Xiao H; Xiong G; Wang X; Zhao Q; Cong Y; Yu Z
Biochem Biophys Res Commun; 2018 Jul; 502(1):110-115. PubMed ID: 29787755
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Kasner MT; Mick R; Jeschke GR; Carabasi M; Filicko-O'Hara J; Flomenberg N; Frey NV; Hexner EO; Luger SM; Loren AW; Mangan JK; Wagner JL; Weiss M; Carroll M; Perl AE
Invest New Drugs; 2018 Aug; 36(4):657-666. PubMed ID: 29607465
[TBL] [Abstract][Full Text] [Related]
11. Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells.
Gao J; Fan M; Xiang G; Wang J; Zhang X; Guo W; Wu X; Sun Y; Gu Y; Ge H; Tan R; Qiu H; Shen Y; Xu Q
Cell Death Dis; 2017 May; 8(5):e2765. PubMed ID: 28471454
[TBL] [Abstract][Full Text] [Related]
12. Staurosporine enhances ATRA-induced granulocytic differentiation in human leukemia U937 cells via the MEK/ERK signaling pathway.
Shi L; Weng XQ; Sheng Y; Wu J; Ding M; Cai X
Oncol Rep; 2016 Nov; 36(5):3072-3080. PubMed ID: 27665842
[TBL] [Abstract][Full Text] [Related]
13. The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.
Shao X; Liu Y; Li Y; Xian M; Zhou Q; Yang B; Ying M; He Q
Sci Rep; 2016 Apr; 6():24589. PubMed ID: 27074819
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia.
Döhner H; Weisdorf DJ; Bloomfield CD
N Engl J Med; 2015 Sep; 373(12):1136-52. PubMed ID: 26376137
[No Abstract] [Full Text] [Related]
15. A PU.1 suppressive target gene, metallothionein 1G, inhibits retinoic acid-induced NB4 cell differentiation.
Hirako N; Nakano H; Takahashi S
PLoS One; 2014; 9(7):e103282. PubMed ID: 25072246
[TBL] [Abstract][Full Text] [Related]
16. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Bertacchini J; Guida M; Accordi B; Mediani L; Martelli AM; Barozzi P; Petricoin E; Liotta L; Milani G; Giordan M; Luppi M; Forghieri F; De Pol A; Cocco L; Basso G; Marmiroli S
Leukemia; 2014 Nov; 28(11):2197-205. PubMed ID: 24699302
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
Sampath D; Malik A; Plunkett W; Nowak B; Williams B; Burton M; Verstovsek S; Faderl S; Garcia-Manero G; List AF; Sebti S; Kantarjian HM; Ravandi F; Lancet JE
Leuk Res; 2013 Nov; 37(11):1461-7. PubMed ID: 23993427
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
Park S; Chapuis N; Saint Marcoux F; Recher C; Prebet T; Chevallier P; Cahn JY; Leguay T; Bories P; Witz F; Lamy T; Mayeux P; Lacombe C; Demur C; Tamburini J; Merlat A; Delepine R; Vey N; Dreyfus F; Béné MC; Ifrah N; Bouscary D;
Leukemia; 2013 Jul; 27(7):1479-86. PubMed ID: 23321953
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
